ATE216425T1 - Verwendung von interferon-gamma zur vermeidung der proliferation und differenzierung der primitiven hämapoietischen vorläuferzellen - Google Patents

Verwendung von interferon-gamma zur vermeidung der proliferation und differenzierung der primitiven hämapoietischen vorläuferzellen

Info

Publication number
ATE216425T1
ATE216425T1 AT95112000T AT95112000T ATE216425T1 AT E216425 T1 ATE216425 T1 AT E216425T1 AT 95112000 T AT95112000 T AT 95112000T AT 95112000 T AT95112000 T AT 95112000T AT E216425 T1 ATE216425 T1 AT E216425T1
Authority
AT
Austria
Prior art keywords
cells
gamma
primitive
pronector
hemapoietic
Prior art date
Application number
AT95112000T
Other languages
English (en)
Inventor
Zwi Prof Bernemann
Bockstaele Dirk Dr Van
Hans-Willem Dr Snoeck
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Application granted granted Critical
Publication of ATE216425T1 publication Critical patent/ATE216425T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95112000T 1994-08-13 1995-07-31 Verwendung von interferon-gamma zur vermeidung der proliferation und differenzierung der primitiven hämapoietischen vorläuferzellen ATE216425T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94112688 1994-08-13

Publications (1)

Publication Number Publication Date
ATE216425T1 true ATE216425T1 (de) 2002-05-15

Family

ID=8216202

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95112000T ATE216425T1 (de) 1994-08-13 1995-07-31 Verwendung von interferon-gamma zur vermeidung der proliferation und differenzierung der primitiven hämapoietischen vorläuferzellen

Country Status (5)

Country Link
US (1) US5807744A (de)
JP (1) JP2846605B2 (de)
AT (1) ATE216425T1 (de)
CA (1) CA2155920A1 (de)
DE (1) DE69526395D1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1867397A (en) 1995-11-16 1997-06-05 Michael W. Dahm Method of quantifying tumour cells in a body fluid and a suitable test kit
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US6573253B2 (en) 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
DE19804372A1 (de) 1998-02-04 1999-08-05 Michael W Dr Dr Dahm Verfahren zur quantitativen Bestimmung von Tumorzellen in einer Körperflüssigkeit und dazu geeignete Testkits
WO1999047158A2 (en) * 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
DE19904267A1 (de) 1999-02-03 2000-08-10 Michael W Dahm Verfahren zur Anreicherung von Tumorzellen aus einer Körperflüssigkeit und dazu geeigneter Kit
US20050059584A1 (en) * 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7378098B2 (en) * 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US7368425B2 (en) * 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
CA2335109A1 (en) * 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US6515001B2 (en) 2001-03-05 2003-02-04 Chemokine Therapeutic Corporation IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
US7053072B2 (en) * 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
CN105131104B (zh) 2001-10-10 2018-11-16 诺和诺德公司 肽的重构和糖缀合

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714680B1 (en) * 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
ES2076378T5 (es) * 1989-09-25 1999-10-16 Genetics Inst Metodo para la inhibicion del desarrollo de celulas de tallo.

Also Published As

Publication number Publication date
JPH0898679A (ja) 1996-04-16
CA2155920A1 (en) 1996-02-14
JP2846605B2 (ja) 1999-01-13
DE69526395D1 (de) 2002-05-23
US5807744A (en) 1998-09-15

Similar Documents

Publication Publication Date Title
ATE216425T1 (de) Verwendung von interferon-gamma zur vermeidung der proliferation und differenzierung der primitiven hämapoietischen vorläuferzellen
ATE264692T1 (de) Verwendung von no synthase hemmern und fängern von reaktiven sauerstoffsformen zur behandlung von ischämie
DE3161494D1 (en) Cosmetic preparations
ATE124421T1 (de) Verfahren zur wachstumshemmung von stammzellen.
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
DE69535328D1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
YU45871B (sh) Polipeptid sa humanim imunointerferonskim (ifn-gama) svojstvima
ATE254443T1 (de) Inhibitierung des haarwuchses
IL98957A0 (en) Immunotherapy with interleukin-7
DE69530403D1 (de) Analogen des keratinozytenwachstumfaktors
NZ335108A (en) Methods of inhibiting stem cell proliferation by contacting hematopoietic cells with an inhibiting amount of INPROL
Papas et al. Analysis of the amino acid binding to the proline transfer ribonucleic acid synthetase of Escherichia coli
MY106202A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof.
ATE219061T1 (de) Huperzin a analoge verbindungen
FI925946A7 (fi) Uusia 2-sakkarinyylimetyyliaryyli- ja -aryylioksiasetaatteja, jotka ovat käyttökelpoisia proteolyyttisten entsyymien inhibiittoreina, niitä sisältäviä koostumuksia ja niiden käyttö
FI925947A7 (fi) Uusia heterosyklisiä 2-sakkarinyylimetyylikarboksylaatteja, jotka ovatkäyttökelpoisia proteolyyttisten entsyymien inhibiittoreina, niitä sisältäviä koostumuksia ja niiden käyttö
LTIP610A (en) Inhibitors of cells proliferation, pharmaceutical composition and method for preparation of compounds
DE69624937D1 (de) Verfahren zur verminderung der strahlentherapie oder der radiomimetischen chemotherapie bei der transplantation von hematopoietischen, pluripotenten zellen
IL95875A0 (en) Illudin analogs,pharmaceutical compositions containing the same and methods for the use thereof
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
DE69722202D1 (de) Dihydrobenzopyran und ähnliche verbindungen verwendbar als antientzündungsmittel
MY132553A (en) Methods of making hiv-protease inhibitors and intermediates for making hiv-protease inhibitors
ATE342062T1 (de) Angiotensin ii zur verbesserung der befruchtung
HUT66153A (en) Pharmaceutical compositions which can be used for preventing and treating of chemotherapy-induced alopecia
DE69528473D1 (de) Verwendung von hepatozyten-wachstumsfaktor zur induzierung der proliferation und differenzierung von hämatopoietischen zellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties